- Home
- RIGL vs BRW Comparison
RIGL vs BRW Comparison
Compare RIGL & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BRW
- Stock Information
- Founded
- RIGL 1996
- BRW 1987
- Country
- RIGL United States
- BRW United States
- Employees
- RIGL N/A
- BRW N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BRW Trusts Except Educational Religious and Charitable
- Sector
- RIGL Health Care
- BRW Finance
- Exchange
- RIGL Nasdaq
- BRW Nasdaq
- Market Cap
- RIGL 335.5M
- BRW 355.1M
- IPO Year
- RIGL 2000
- BRW N/A
- Fundamental
- Price
- RIGL $38.85
- BRW $8.31
- Analyst Decision
- RIGL Buy
- BRW
- Analyst Count
- RIGL 5
- BRW 0
- Target Price
- RIGL $38.20
- BRW N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- BRW 222.1K
- Earning Date
- RIGL 08-05-2025
- BRW 01-01-0001
- Dividend Yield
- RIGL N/A
- BRW 15.59%
- EPS Growth
- RIGL N/A
- BRW N/A
- EPS
- RIGL 5.43
- BRW N/A
- Revenue
- RIGL $267,921,000.00
- BRW N/A
- Revenue This Year
- RIGL $59.93
- BRW N/A
- Revenue Next Year
- RIGL N/A
- BRW N/A
- P/E Ratio
- RIGL $7.15
- BRW N/A
- Revenue Growth
- RIGL 105.62
- BRW N/A
- 52 Week Low
- RIGL $12.66
- BRW $7.15
- 52 Week High
- RIGL $43.72
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- BRW 50.04
- Support Level
- RIGL $39.00
- BRW $8.24
- Resistance Level
- RIGL $42.08
- BRW $8.46
- Average True Range (ATR)
- RIGL 2.32
- BRW 0.08
- MACD
- RIGL -0.37
- BRW -0.01
- Stochastic Oscillator
- RIGL 53.26
- BRW 31.82
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.